Leukoreduction by centrifugation does not eliminate trypanosoma cruzi from infected blood units

Vector-Borne and Zoonotic Diseases

Volumn 9, Issue 3, 2009, Pages 235-241

  Dzib, Doris ^a   Hernández, Virginia Peña ^a   Ake, Baldemar Canche ^a   López, Ruth Alacantara ^b   Monteón, Victor Manuel ^b,c  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE CAMPECHE   (Mexico)

^c Patricio Trueba s n   (Mexico)

Author keywords

Borne; Immunology; Leishmania; Trypanosome; Vector

Indexed keywords

DNA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4;

ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; CELL FRACTIONATION; CENTRIFUGATION; CHAGAS DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; ERYTHROCYTE; HEART DISEASE; HUMAN; LEUKOREDUCTION; MEXICO; MICROORGANISM; NONHUMAN; PARASITE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROPREVALENCE; TRYPANOSOMA CRUZI;

TRYPANOSOMA CRUZI;

EID: 68049131392     PISSN: 15303667     EISSN: None     Source Type: Journal    
DOI: 10.1089/vbz.2007.0278     Document Type: Article

References (31)

1. Becerril-Flores, MA, Rangel-Flores, E, Imbert-Palofox, J, Gomez-Gomez, JV, Figueroa-Gutierrez, AH. Human infection and risk of transmission of Chagas disease in Hidalgo State, México. Am J Trop Med Hyg 2007; 76:318-323.
2. Beckman, N, Cardigan, R, Willington, T, Willianson, LM. Value of central analysis of leukocytes depletion quality control data within the national blood service, England. Vox Sang 2002; 83:110-118.
3. Cardo, LJ, Salata, J, Mendéz, J, Reddy, H, Goodrich, R. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrate using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 38:131-137.
4. Castro, E, Girones, N, Bueno, JL, Carrión, J, et al. The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. Transfusion 2007; 47:434-441.
5. Coronado, X, Ortíz, S, Larrondo, M, Rozas, M, Solari, A. Inestability of Trypanosoma cruzi DNA in blood lysates: Importance for PCR DNA-based diagnosis. Mol Diagn 2005; 9:35-40.
6. Degrave, W, Fragoso, SP, Brito, C, et al. Peculiar sequence organization of kinetoplast DNA minicircles from Trypanosoma cruzi. Mol Biochem Parasitol 1988; 27:63-70.
7. De Titto, E, Braun, M, Segura, E. Density gradient purification of human lymphocytes from contaminating trypomastigotes of Trypanosoma cruzi. J Immunol Methods 1982; 50:281-287.
8. Dodd, RY. Current risk for transfusion transmitted infections. Curr Opin Hematol 2007; 14:671-676.
9. Dumonteil, E, Goubiere, S, et al. Geographic distribution of Tri-atoma dimidata and transmission dynamics of Trypanosoma cruzi on the Yucatan Peninsula of Mexico. Am J Top Med Hyg 2002;67:176-183.
10. Guevara, AG, Garzon, E, Bowen, C, Cordova, X, et al. High infection rates of Triatoma dimidiata are associated with low levels of Trypanosoma cruzi seroprevalence in Pedro Carbo, Ecuador. Use of a Tc 24 gene-based PCR approach. Parasite 2005;12:65-68.
11. Guzman-Bracho, C, Garcia-Garcia, L, Floriani-Verdugo, J, Guer-rero-Martínez, S, et al. Riesgo de transmisión de Trypanosoma cruzi por transfusión de sangre en México. Rev Panam Salud Publica 1998; 4:94-98.
12. Hernandez-Becerril, N, Mejia, AM, Ballinas-Verdugo, M, et al. Blood transfusion and iatrogenic risk in México city: anti-Trypanosoma cruzi seroprevalence in 43048 blood donors, evaluation of parasitemia and electrocardiogram findings in seropositive. Mem Inst Oswaldo Cruz 2005; 100:111-116.
13. Hernandez-Becerril, N, Nava, A, Reyes, PA, Monteón, VM. IgG subclass reactivity to Trypanosoma cruzi in chronic chagasic patients. Arch Cardiol Mex 2001; 71:199-205.
14. Jeffris, R. Selective IgG subclass deficiency: quantification and clinical relevance. Clin Exp Immunol 1990; 81:357-367.
15. Leiby, DA, Herron, RM, Read, EJ, Lenes, BA, Stumpf, RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002; 42:549-555.
16. Lundren, M, Persson, V, Larsson, V. Interleukin.4 induces synthesis of IgE and IgG4 in humans B cells. Eur J Immunol 1989; 19:1311-1315.
17. Moraes-Souza, H, Bordin, J, Bardossy, L, MacPherson, D, Bla-jchman, M. Prevention of transfusion-associated Chagas' disease: efficacy of white cell-reduction filters in removing Trypanosoma cruzi from infected blood. Transfusion 1995; 35:723-726.
18. Pellegrino, J. Transmiss?o da doença de Chagas pela transfus?o de sangue. Primeras comprovaç?es serologicas em donadores e em candidatos a doadores de sangue. Rev Bras Med 1949; 6:297-301.
19. Pinto, DJC, Brener, S. Chagas' disease and blood transfusion. Mem Inst Oswaldo Cruz 1984; 79:139-147.
20. Pruss, A, Kalus, V, Radtke, H, Baumann-Baretti, B, et al. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions. Transfus Apher Sci 2004; 30:41-46.
21. Ramírez, LE, Lages-Silva, E, Pianetti, GM, Robelo, R, et al. Prevention of transfusion-associated Chagas' disease by sterilization of Trypanosoma cruzi- infected blood with gentian violent, ascorbic acid and light. Transfusion 1995; 35:226-230.
22. Ramos-Ligonio, A, Ramírez-Sánchez, M, González- Hernández, JC, Rosales-Encina, J, López-Monteón, A. Prevalencia de anticuerpos contra Trypanosoma cruzi en donadores de sangre del IMSS, Orizaba, Veracruz, México. Salud Publica Mex 2006; 48:13-21.
23. Rangel-Flores, H, Sánchez, B, Mendoza-Duarte, J, Barnabé, C, et al. Serologic and parasitologic demonstration of Trypanosoma cruzi infections in a urban area of central México: correlation with electrocardiographic alterations. Am J Trop Med Hyg 2001; 65:887-895.
24. Rodríguez-Felix, ME, Zavala-Velázquez, JE, Barrera-Pérez, MA, Guzmán-Marin, E, et al. Riesgo de transmisión de la enfermedad de Chagas por donantes de sangre. Rev Biomédica (México) 1995; 6:70-75.
25. Sanchéz-Guillen, MC, Velásquez-Rojas, M, Martínez-Mungia, J, et al. High prevalence anti-Trypanosoma cruzi antibodies, among blood donors in the state of Puebla a non-endemic area of México. Mem Inst Oswaldo Cruz 2002; 97:947-952.
26. Schmunis, G. Risk of Chagas disease through transfusion in the Americas. Medicina (B Aires) 1999; 59:125-134.
27. Smith, K, Cobain, T, Dustan, R. Removal of cytomegalovirus DNA from donor blood by filtration. Br J Haematol 1993; 83:640-642.
28. Trujillo-Contreras, F, Lozano-Kasten, F, Soto-Gutiérrez, M, Hernández-Gutiérrez, R. Prevalencia de infección a Trypanosoma cruzi en donadores de sangre en el estado de Jalisco, México. Rev Soc Bras Med Trop 1993; 26:89-92.
29. Van Vorrhis, WC, Barret, LK, Eastman, T, Alfonso, R, Dupuis, K. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chem 2003; 47: 475-479.
30. Wendel, S, Pinto, DJC. Transfusion transmitted Chagas disease. In: S. Wendel, Z. Brenner, M.E. Camargo, A. Rossi, eds. Chagas Disease (American Tripanosomiasis): Its Impact on Transfusion and Clinical Medicine. ISBT Brazil 92, Sao Paulo, Brasil, 1992: 103-133.
31. Ziemann, M, Mair, AB, Unmack, A, Herring, H. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007; 47:1972-1983.